title: Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors.
abstract: In order to develop new selective COX-2 inhibitors, a new series of 2-phenyl-4H-chromen-4-one derivatives possessing a methylsulfonyl pharmacophore group at the para position of the C-4 phenyl ring were designed, synthesized, and evaluated for cyclooxygenase-2 inhibitory activity. In vitro COX-1/COX-2 isozyme inhibition structure-activity studies identified 3-(benzyloxy)-2-[4-(methylsulfonyl)phenyl]-4H-chromen-4-one (5d) as a potent COX-2 inhibitor (IC50 = 0.07 μM) with a high COX-2 selectivity index (SI = 287.1) comparable to the reference drug celecoxib (COX-2 IC50 = 0.06 μM; COX-2 SI = 405). A molecular modeling study where 3-(benzyloxy)-2-[4-(methylsulfonyl)phenyl]-4H-chromen-4-one (5d) was docked into the active site of COX-2 showed that the p-MeSO2 substituent on the C-4 phenyl ring was well-oriented in the vicinity of the COX-2 secondary pocket (Arg(513), Val(523), and His(90)) and the carbonyl group of the chromene ring could interact with Ser(530). The structure-activity data acquired indicated that the nature and size of the substituent on the C-3 chromene scaffold are important for COX-2 inhibitory activity. Our results also indicated that the chromene moiety constitutes a suitable template to design new COX-2 inhibitors.
authors.affiliation: Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Afshin
authors.initials: A
authors.lastname: Zarghi
authors.affiliation: Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Samaneh
authors.initials: S
authors.lastname: Kakhki
keywords: COX-2 inhibitory activity; Chromene derivatives; Docking studies
references.citation: Annu Rev Biochem. 2000;69:145-82
references.pmid: 10966456
references.citation: Nature. 1996 Dec 19-26;384(6610):644-8
references.pmid: 8967954
references.citation: Bioorg Med Chem. 2009 Jul 15;17(14):5312-7
references.pmid: 19560931
references.citation: Crit Rev Oncol Hematol. 2004 Nov;52(2):81-101
references.pmid: 15501074
references.citation: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:187-96
references.pmid: 12432918
references.citation: J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S35-40
references.pmid: 11992749
references.citation: Baillieres Best Pract Res Clin Gastroenterol. 2000 Feb;14(1):147-59
references.pmid: 10749095
references.citation: Neurosci Lett. 2011 Jan 3;487(1):83-7
references.pmid: 20934488
references.citation: Bioorg Med Chem Lett. 2007 Oct 15;17(20):5634-7
references.pmid: 17822894
references.citation: Bioorg Med Chem. 2006 Apr 15;14(8):2600-5
references.pmid: 16356730
references.citation: J Pain Symptom Manage. 2003 Feb;25(2 Suppl):S32-40
references.pmid: 12604155
references.citation: Am J Med. 1999 May 31;106(5B):3S-12S
references.pmid: 10390123
references.citation: Adv Drug Deliv Rev. 2002 Dec 7;54(12):1627-56
references.pmid: 12453679
references.citation: Toxicol Lett. 2000 Mar 15;112-113:493-8
references.pmid: 10720771
references.citation: J Cardiovasc Pharmacol. 2006;47 Suppl 1:S7-14
references.pmid: 16785833
references.citation: Baillieres Clin Rheumatol. 1988 Aug;2(2):425-54
references.pmid: 3066501
references.citation: Trends Pharmacol Sci. 1999 Nov;20(11):465-9
references.pmid: 10542447
references.citation: Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):147-54
references.pmid: 17164142
references.citation: Neurobiol Aging. 2002 May-Jun;23(3):327-34
references.pmid: 11959394
references.citation: Bioorg Med Chem Lett. 2003 Feb 10;13(3):413-7
references.pmid: 12565941